Meeting
2016 ASCO Annual Meeting
Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Authors
Christian Grommes
Memorial Sloan Kettering Cancer Center, New York, NY
Christian Grommes , Thomas Joseph Kaley , Craig Nolan , Antonio Marcilio Padula Omuro , Julia Wolfe , Ingo K. Mellinghoff , Lisa Marie DeAngelis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02315326
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2046)
DOI
10.1200/JCO.2016.34.15_suppl.2046
Abstract #
2046
Poster Bd #
233
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma.
First Author: Christian Grommes
Poster
2017 ASCO Annual Meeting
Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
First Author: Christian Grommes
Poster
2020 ASCO Virtual Scientific Program
Ibrutinib-based combination therapy exhibited therapeutic benefit in newly diagnosed primary central nervous system lymphoma.
First Author: Feili Chen
Poster
2023 ASCO Annual Meeting
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
First Author: Marion Alcantara